The Company expects gross margin for the full year 2023 to fall within the range of 73% to 74%.Pulmonx expects total operating expenses for the full year 2023 to fall within the range of $112 million to $114 million, inclusive of approximately $22 million of non-cash stock-based compensation.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on LUNG:
- Pulmonx Reports Fourth Quarter and Full Year 2022 Financial Results
- Pulmonx to Present at the Citi 2023 Healthcare Conference
- Pulmonx to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023
- Point72 Asset Management reports 5.3% passive stake in Pulmonx
- BofA downgrades Pulmonx to Underperform on limited upside potential
